Oct 23, 2023, 15:35
Julien Mazières: Alectinib is the first ALK inhibitor to significantly improve DFS compared with CT
Julien Mazières, Thoracic Oncology Specialist at Toulouse University Hospital, France, shared insights from the ALINA study from ESMO23 on X/Twitter:
“Another big hit ESMO 23. Alectinib is the first ALK inhibitor to significantly improve DFS compared with CT. Impressive curves and HR 0.24. Immediate practice-changing trial.”
Source: Julien Mazières/Twitter.
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 2, 2024, 03:30
Nov 2, 2024, 03:27
Nov 2, 2024, 03:21
Nov 2, 2024, 03:18
Nov 2, 2024, 03:16